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Abstract
Background: Uterine fibroids have a disproportionate impact on African-American women. There are, however,
no data to compare racial differences in symptoms, quality of life, effect on employment, and information-
seeking behavior for this disease.
Methods: An online survey was conducted by Harris Interactive between December 1, 2011 and January 16,
2012. Participants were U.S. women aged 29–59 with symptomatic uterine fibroids. African-American women
were oversampled to allow statistical comparison of this high-risk group. Bivariate comparison of continuous
and categorical measures was based on the t-test and the Chi-squared test, respectively. Multivariable adjust-
ment of risk ratios was based on log binomial regression.
Results: The survey was completed by 268 African-American and 573 white women. There were no differences
between groups in education, employment status, or overall health status. African-American women were
significantly more likely to have severe or very severe symptoms, including heavy or prolonged menses
(RR = 1.51, 95% CI 1.05–2.18) and anemia (RR = 2.73, 95% CI 1.47–5.09). They also more often reported that
fibroids interfered with physical activities (RR = 1.67, 95% CI 1.20–2.32) and relationships (RR = 2.27, 95% CI
1.23–4.22) and were more likely to miss days from work (RR = 1.77, 95% CI 1.20–2.61). African-American women
were more likely to consult friends and family (36 vs. 22%, P = 0.004) and health brochures (32 vs. 18%, P < 0.001)
for health information. Concerns for future fertility (RR = 2.65, 95% CI 1.93–3.63) and pregnancy (RR = 2.89, 95%
CI 2.11–3.97) following fibroid treatments were key concerns for black women.
Conclusions: African-American women have more severe symptoms, unique concerns, and different informa-
tion-seeking behavior for fibroids.
Introduction
Uterine fibroids or leiomyomas are benign tumors ofthe uterine muscle (myometrium) and the leading cause
of hysterectomy.1 Fibroids are clinically detectable in 25% to
80% of women in community-based studies; thus many wo-
men have the disease without receiving any treatment.2 Little
is known about the clinical burden of symptomatic fibroid
disease or about the decision-making process regarding fi-
broid therapies.3,4
Multiple lines of evidence suggest that uterine fibroids have
a disproportional effect on African-American women. African-
American women have a higher cumulative risk of uterine
fibroids,2 a threefold greater incidence and relative risk of fi-
broids,5,6 and an earlier age of onset.7 In addition, African-
American women are 2.4 times more likely to undergo
hysterectomy and have an 6.8-fold increase of undergoing
uterine-sparing myomectomy.8 At the time of hysterectomy,
African-American women have higher uterine weights, more
fibroids, a higher likelihood of preoperative anemia, and more
severe pelvic pain.9 Data also suggests that African-American
women may have biologically distinct disease.7,10–12
The 2011 evidence review on fibroids conducted by the
United States’ Agency for Healthcare Research and Quality
(AHRQ) provided a comprehensive assessment of multiple
areas where additional research regarding uterine fibroids is
needed.13 The AHRQ report included as prioritized research
questions assessing the ‘‘burden of disease’’ and how
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‘‘acquisition and processing of available information’’ allow
patients and providers to ‘‘identify and choose strategies for
fibroid management.’’ This study was designed to fill this
research gap by conducting a survey in a racially diverse co-
hort of women with symptomatic uterine fibroids. The only
prior survey of women with fibroids did not include infor-
mation on race; this omission is a common problem in fibroid
research and a critical one given the disproportionate impact
of this disease on women of African descent.14,15
Finally, understanding the perspective of disease from the
patient’s point of view is seen as increasingly important to
optimize health. For uterine fibroids, obtaining this informa-
tion is very timely given that uterine fibroids are one of the
three high-impact research topics announced by the Patient
Centered Outcomes Research Institute for 2013 (http://
www.pcori.org/2013/san-francisco-meeting/).
Materials and Methods
This survey was investigator designed and funded by Fi-
broid Relief, a program of the nonprofit Focused Ultrasound
Foundation (Charlottesville, Virginia). It was conducted by
Harris Interactive (Rochester, New York) between December
1, 2011 and January 16, 2012.
The methodology of the Harris Interactive online survey
has been utilized and reported in a variety of medical settings,
including surveys assessing awareness of cardiovascular
disease in women, medication errors in geriatric patients, the
impact of impaired walking ability on individuals diagnosed
with multiple sclerosis, and assessment of school readiness in
children diagnosed with behavioral problems.16–19 The goal
of the online panel is to provide a representative sample of the
general population while identifying and reaching under-
represented populations of interest. Panel respondents are
recruited from a variety of sources, including co-registration
offers on partners’ websites, targeted emails sent by online
partners to their audiences, graphical and text banner place-
ment on partners’ websites (including social media, news,
search, and community portals), trade show presentations,
targeted postal mail invitations, and telephone recruitment of
targeted populations. Each recruitment source is carefully
vetted through a rigorous interviewing and testing process
and then monitored for response quality on an ongoing basis.
A weighting algorithm is utilized, which involves pro-
pensity score adjustment to minimize biases due to nonran-
dom selection inherent in Internet-based surveys.20 Data were
weighted by age, education, region, and income categories
based on the March 2010 Current Population Survey data
(http://www.census.gov/cps/) to reflect a nationally repre-
sentative sample of women.
Women 29 to 59 years of age with a self-reported diagnosis
of uterine fibroids and fibroid symptoms within the last two
years were recruited and screened from Harris Interactive’s
online panel for our survey. Exclusion criteria included wo-
men who were pregnant or breastfeeding or who had un-
dergone a hysterectomy. Women in the sample pool who
appeared to be eligible received an email briefly describing
the study, and women who were interested in participating
were directed to the survey website where the survey could be
completed. The survey was administered in English with the
goal of 1000 respondents. The Mayo Clinic Institutional Re-
view Board determined this research to be exempt.
Race was assessed by asking ‘‘Do you consider yourself:
White, African-American/African/African-American/Afro-
Caribbean, Asian or Pacific Islander, Native American or
Alaskan Native, Mixed race, Some other race or Decline to
answer.’’ The respondent’s state of residence was collected
and categorized in terms of the U.S. Census Bureau’s regional
designations (https://www.census.gov/geo/www/us_reg
div.pdf).
For symptomatic outcomes, a five-point Likert scale en-
compassing very severe, severe, moderate, mild, and very
mild was used. Women were also allowed to report that they
did not experience the specific symptom within the preceding
three months. Some questions were adapted with permission
from the validated Uterine Fibroid Symptoms and Quality of
Life (UFS-QOL) instrument.21 The five-point Likert scale of
the UFS-QOL utilizes the responses all of the time, most of the
time, some of the time, a little of the time, and none of the time
Outcomes describing activity and information- seeking
experiences associated with uterine fibroids were captured
in a four-point Likert scale encompassing the following
responses: strongly agree/somewhat agree,/somewhat dis-
agree/strongly disagree, very important/important/some-
what important/not at all important, very concerned/
concerned/somewhat concerned/not at all concerned, or
very likely, likely/somewhat likely/not at all likely, as ap-
propriate.
Statistical analysis
Data weighted on the basis of age, education, region, and
income categories are presented as mean values or percent-
ages. Statistical comparison of continuous measures was
based on the t-test of differences, and categorical measures
were based on the Chi-squared test. To facilitate interpreta-
tion, the reported results were dichotomized based on whe-
ther subjects reported any of the top two categories (e.g., very
severe or severe for the five-point Likert responses, and
strongly agree or somewhat agree for the four-point Likert
scale responses). Multivariable adjustment of risk ratios was
performed using log binomial regression. In order to assess
potential risk modification by age groups, marital status, in-
come, and education on the association between race and
reported outcomes, separate regression models were devel-
oped for each of these stratifications. Statistical analyses were
performed using Stata SE Version 11.2 (College Station,
Texas).
Results
The survey was presented online to 140,231 women, and of
these 23% (32,723) started the survey. Nine hundred and
sixty-eight women or 3% of those starting the survey both
were eligible and went on to complete the survey. This re-
sponse rate was similar to rates in other online women’s heath
surveys using similar methodology.16 The survey required an
average of 20 minutes to complete. Fifty-nine percent of par-
ticipants were white, 28% were African-American, and 12%
were of other races. This study reports only on white (n = 573)
and African-American (n = 268) women. so that a direct
comparison based on race could be presented. Table 1 pres-
ents the demographic characteristics of the overall sample.
The mean age of surveyed women was 45.25 years, and over
three-quarters were in good to excellent health (74%). Most
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women were parous and married or living with a partner
(69% for both). A minimum of 20% of the sample came from
each of the four geographic regions, and half of the surveyed
women were employed full time (50%). Seventy- two percent
had completed at least some college education, and 42%
earned in excess of $75,000 annually.
There were no significant differences between African-
American and white women in our survey in employment
status, education, number of children, time since diagnosis,
and overall health status (Table 1). However, African-
American women were significantly younger, had lower
incomes, notably different marital status, and differing geo-
graphic locations.
The prevalence of specific severe or very severe uterine
fibroid symptoms over the preceding three months ranged
from 8% to 29%, with African-American women generally
reporting higher occurrence of symptoms compared to their
white counterparts (Table 2). Menstrual pain and cramps
(29%) were most commonly reported as severe, closely fol-
lowed by heavy or prolonged menstrual bleeding (28%).
The adjusted risk ratios (RR) that correct for differences in
baseline characteristics demonstrate that African-American
women were significantly more likely to report severe or very
severe symptoms compared to white women for most symp-
toms (Table 2). The likelihood of African-American women
reporting abdominal bloating, pressure, and protrusion was
two times higher (RR = 2.14, 95% Confidence Interval [CI] 1.43
to 3.21), and anemia was nearly three times higher (RR = 2.73,
95% CI 1.47 to 5.09) than for white women. African-American
women were significantly more impacted by heavy or pro-
longed menses, (RR = 1.51, 95% CI 1.05 to 2.18), menstrual
cramps (RR = 1.80, 95% CI 1.30 to 2.51), passage clots during
their period (RR = 1.67, 95% CI 1.20 to 2.32), and abdominal
tightness or cramping (RR = 1.79, 95% CI 1.21 to 2.65).
Between 14% and 22% of women felt that fibroids inter-
fered with intrapersonal relationships. African-American
Table 1. Characteristics of the Survey Population
Variable Overall (n = 841) African-American (n = 268) White (n = 573) P Value
Age (mean in years) 45.25 43.54 46.04 0.002
Time since diagnosis (mean in months) 8.98 9.53 8.72 0.31
Employment status (%) 0.71
Employed full time 50 48 51
Employed part time 15 13 16
Not employed 31 34 29
Student/retired 4 5 4
Education (%) 0.19
High school or less 28 34 26
Some college 34 36 34
College graduate 24 20 27
Some graduate school 13 11 14
Annual income category (%) < 0.001
< $35K 24 40 17
$35 – < $50K 15 15 15
$50K – < $75K 19 15 22
$75K or more 42 31 47
Marital status (%) < 0.01
Never married 17 30 11
Married/civil union/living with partner 69 53 77
Divorced/separated 12 16 10
Widow/widower 2 1 3
Number of children (%) 0.98
No children 31 32 31
Between 1b 2 46 46 46
3 or more 23 22 23
Overall health status (%) 0.12
Fair/poor 24 30 22
Good 46 46 47
Very good/excellent 29 24 32
Age groups (%) 0.03
29–39 24 31 21
40–49 45 47 44
50–59 30 22 34
Geographic locations (%) 0.001
Northeast 24 23 25
Midwest 21 20 22
South 35 48 29
West 20 10 25
Note: Survey weights are used to generate the above numbers.
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women were significantly more likely to experience impair-
ment of their relationship with friends and family (RR = 2.27,
95% CI 1.23 to 4.22) (Table 2). Fibroids also affected women’s
relationship with their ‘‘significant others’’ (22%) and their
ability to care for their home and/or children (14%); however,
African-American and ehite women did not differ signifi-
cantly on these measures. Approximately one-fifth (22%) of all
women reported feeling a negative sense of femininity or
sexuality.
African-American women reported greater employment-
related concerns than white women (Table 2). However, fol-
lowing multivariable adjustment, only the risk ratio associ-
ated with missed days of work was found to be significant.
African-American women were 77% more like to miss work
than their white counterparts (RR = 1.77, 95% CI 1.20 to 2.61).
Concerns regarding physical impairment due to fibroids
were very common overall (Table 3). Most women (77%) were
afraid of future fibroid growth, and African-American wo-
men were more likely to report this fear (RR = 1.14, 95% CI
1.03 to 1.26). More than half of all women were concerned that
fibroids would be associated with future health complications
(61%), that they would need a hysterectomy (55%), that the
fibroids would turn into a cancer (51%), that the fibroids
would affect their sex life (52%), that fibroids would affect
their relationship with their husbands/significant others
(42%), or that their bodies would never be normal again (46%)
(Table 3). However, adjusted risk ratios for these concerns
were not significantly different for African-American and
white women following adjustment for confounders. African-
American women were significantly more concerned that
their fibroids would affect their ability to have a successful
and healthy pregnancy (RR = 2.05, 95% CI = 1.51 to 2.78) and
that their fibroids would make them depressed (RR = 1.34,
95% CI 1.02 to 1.26) (Table 3).
This concern for future pregnancy was echoed in African-
American women’s perceptions of treatment options (Table
3). They were more likely to value a treatment option that
preserved their ability to get pregnant (RR = 2.89, 95% CI 2.11
to 3.97). Moreover, African-American women were more
likely to view a uterine-preserving treatment option as very
important than were white women (RR = 2.66, 95% CI 1.76 to
4.01). Similarly, African-American women were almost three
times as likely to be concerned about the effects of fibroid
treatment on fertility (RR = 2.65, 95% CI 1.93 to 3.63).
African-American women were more concerned about all
of the queried concerns regarding fibroid treatment and had
significantly more concerns than white women on almost all
measures (Table 3). Most women (81%) were concerned about
the invasiveness of fibroid surgery, with a significantly higher
proportion of African-American women reporting this con-
cern (RR = 1.11, 95% CI 1.03 to 1.20). Postoperative pain
(RR = 1.12, 95% CI 1.01 to 1.23), permanence of the treatment
(RR = 1.24, 95% CI 1.12 to 1.37), and potential scarring
(RR = 1.54, 95% CI 1.32 to 1.80) also differed significantly be-
tween groups.
Overall, African-American women reported more quality
of life impairment compared to white women on most queried
measures, and there were also many areas where African-










Symptoms (symptoms reported severe or very severe)
Abdominal bloating and pressure/protruding abdomen (%) 22 37 15 2.14 (1.43, 3.21)
Passing blood clots during your menstrual period (%) 26 40 20 1.67 (1.20, 2.32)
Heavy or prolonged menstrual bleeding (%) 28 37 23 1.51 (1.05, 2.18)
Abdominal pain/cramping/tightness (%) 24 34 19 1.79 (1.21, 2.65)
Anemia (%) 11 22 6 2.73 (1.47, 5.09)
Backache or leg pains (%) 22 28 19 1.33 (0.89, 1.99)
Constipation (%) 9 15 6 1.62 (0.77, 3.40)
Bladder symptoms (%) 9 11 9 1.05 (0.49, 2.29)
Fatigue (%) 25 32 22 1.55 (1.03, 2.32)
Menstrual pain/cramps (%) 29 42 23 1.80 (1.30, 2.51)
Painful intercourse (%) 8 10 7 1.12 (0.58, 2.17)
Lack of interest in sex (%) 18 21 17 1.15 (0.73, 1.82)
Relationships (effects were felt most of the time or all of the time)
Affected your relationship with family/friends (%) 15 22 11 2.27 (1.23, 4.22)
Affected your relationship with husband/significant other (%) 22 29 19 1.42 (0.94, 2.15)
Affected your ability to take care of your home/children (%) 14 21 11 1.59 (0.98, 2.59)
Negatively affected your sense of femininity/sexuality (%) 22 25 20 1.09 (0.72, 1.65)
Employment Concerns (somewhat agree or strongly agree)
Prevented me from carrying out normal work-related or
professional responsibilities (%)
27 34 23 1.21 (0.71, 2.07)
Prevented me from reaching my true potential at work
or in my professional life (%)
24 33 21 1.23 (0.76, 2.01)
Caused me to miss days of work (%) 29 44 23 1.77 (1.20, 2.61)
Made me afraid I’ll lose my job (%) 12 21 9 2.13 (0.95, 4.76)
Prevented me from traveling for work (%) 15 24 11 1.67 (0.74, 3.78)
{Adjustment was based on log-binomial regression that accounts for the confounding factors stated in Table 1.
Survey weights are used to generate the above numbers.
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American women had significantly greater risk-adjusted rates
of impairment (Table 3). The highest level of impairment in this
sample was reported on the UFS-QOL energy/mood subscale,
with 43% of women reporting feeling tired or worn out. Afri-
can-American women were 27% more likely to have these
complaints than white women (RR = 1.27, 95% CI 1.01 to 1.59).
African-American women were significantly more likely to
feel self-conscious about the size and appearance of their
stomach (RR = 2.22, 95% CI 1.77 to 2.79), and about weight
gain (RR = 1.94, 95% CI 1.49 to 2.52) (Table 3). Concerns about
soiling clothes or bedding with menstrual flow was signifi-
cantly more likely for African-American women (RR = 1.88,
95% CI 1.41 to 2.47). Overall, 32% of women reported inter-
ference with physical activities, with African-American wo-
men more affected than their white counterparts (RR = 1.67,
95% CI 1.20 to 2.32). African-American women were signifi-
cantly more likely to have fibroids interfere with daily and
social activities (RR = 1.74, 95% CI 1.21 to 2.48).
Forty-one percent of all women reported seeing two or
more providers, and 5% reported seeing five or more pro-
viders before receiving a diagnosis of fibroids (Table 4). Wo-
men reported having fibroid symptoms for a mean of 3.7









Concerns regarding uterine fibroids
Fibroids will grow (%) 77 84 74 1.14 (1.03, 1.26)
Other possible health complications (%) 61 67 58 1.05 (0.89, 1.23)
I am going to need a hysterectomy (%) 54 55 54 0.94 (0.77, 1.15)
Fibroids might turn into cancer (%) 53 55 52 0.95 (0.78, 1.14)
My fibroids will affect my sex life (%) 52 60 49 1.10 (0.91, 1.33)
My fibroids will affect my relationship
with my husband/significant other (%)
42 50 39 1.14 (0.90, 1.45)
My body will never be normal again (%) 46 55 41 1.24 (0.99, 1.55)
Fibroids will affect my ability to have a
successful & healthy pregnancy (%)
24 39 17 2.05 (1.51, 2.78)
My fibroids will make me depressed (%) 38 47 33 1.34 (1.02, 1.75)
Concerns regarding fibroid treatments
Effect on my ability to have a healthy pregnancy (%) 26 45 17 2.89 (2.11, 3.97)
Effects on my fertility (%) 28 48 19 2.65 (1.93, 3.63)
Effects on my sexuality (%) 64 77 57 1.32 (1.17, 1.49)
How my husband/partner will view me (%) 36 50 30 1.56 (1.19, 2.04)
Effects on my sense of femininity (%) 49 63 43 1.44 (1.19, 1.74)
Undergoing the actual treatment (%) 78 87 74 1.15 (1.06, 1.26)
The invasiveness of the procedure (%) 81 86 78 1.11 (1.03, 1.20)
The permanence of the treatment (%) 72 84 67 1.24 (1.12, 1.37)
Potential for scaring (%) 56 74 47 1.54 (1.32, 1.80)
Number of days missed from work for recovery (%) 71 79 67 1.17 (1.03, 1.33)
Potential loss of income (%) 55 61 52 1.06 (0.81, 1.37)
Inability to take care of my family (%) 57 61 56 1.06 (0.90, 1.25)
Inability to do household chores (%) 59 67 55 1.19 (1.02, 1.39)
Concerns regarding pregnancy and uterine preservation
Treatment option that preserves the ability to get
pregnant in the future (%)
20 35 12 2.66 (1.76, 4.01)
Importance of uterine preserving option (%) 49 70 40 1.76 (1.47, 2.10)
Questions Adopted from the UFS/QOL
Energy/Mood Subscale (Effects were felt most of the time or all of the time)
Caused you to feel tired or worn out (%) 43 53 39 1.27 (1.01, 1.59)
Made you feel sad, discouraged, or hopeless (%) 19 25 16 1.19 (0.82, 1.72)
Self-Conscious Subscale (Effects were felt most of the time or all of the time)
Made you feel conscious about the size and
appearance of your stomach (%)
39 62 28 2.22 (1.77, 2.79)
Made you feel self-conscious about weight gain (%) 38 57 30 1.94 (1.49, 2.52)
Concern Subscale (Effects were felt most of the time or all of the time)
Made you concerned about soiling clothes or bedding (%) 34 49 26 1.88 (1.42, 2.47)
Activities Subscale(Effects were felt most of the time or all of the time)
Interfered with your physical activities (%) 32 45 26 1.67 (1.20, 2.32)
Interfered with your daily and social activities (%) 23 33 18 1.74 (1.21, 2.48)
Control Subscale (Effects were felt most of the time or all of the time)
Made you feel as if you are not in control of your life (%) 21 26 19 1.23 (0.81, 1.88)
{Adjustment was based on log-binomial regression that accounts for the confounding factors stated in Table 1.
Survey weights are used to generate the above numbers.
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years before seeking treatment. This interval is significantly
longer for African-American women than for white women
(4.45 vs. 3.34 years, P = 0.01). Moreover, significantly more
African-American women wait 4 or more years before seeking
treatment (42 vs. 29%, p < 0.001) (Table 4).
Before seeking treatment for fibroids, approximately 60% of
all women employ over-the-counter medications to control
symptoms, half (49%) employ lifestyle modification including
diet and exercise, and a third (34%) utilize hormonal contra-
ceptives (Table 4). About one quarter (26%) of all women utilize
herbs, dietary supplements, or other alternative and comple-
mentary medications; this proportion significantly increases
among African-American women (37 vs. 20%, P < 0.01).
The vast majority (92%) of all women received educational
information about fibroids from a healthcare provider, and
about half (48%) turn to health- related websites (Table 4). A
quarter of all women get information from friends or family
(27%) or health brochures (22%); these two modalities were
used significantly more by African-American women (36 vs.
22 % for friends and family, P < 0.004, and 32% vs. 18% from
brochures, P < 0.001). Few women received information on
fibroids from television and radio (6%), but African-American
women were more than seven times as likely to utilize these
information sources (14 vs. 2%, P < 0.001).
African-American women were also more likely than white
women to view the fibroid information they received as in-
adequate (Table 4). They were significantly more likely to
report needing additional information about fibroids in gen-
eral (54 vs. 29%, P < 0.001), standard treatment options (59%
vs. 39%, P < 0.001), alternative treatment options (58 vs. 39%,
P < 0.004), and the consequences of treatment (58 vs. 37%,
P < 0.001). African-American women were considerably less







(n = 573) P Value
Number of providers seen before diagnosis 0.76
1 59 57 60
2 26 25 27
3 8 10 7
4 2 2 2
5 or more 5 6 4
Time experiencing symptoms before seeking treatment 0.002
Less than 1 year 23 12 28
1–2 Years 21 20 21
2–3 Years 16 17 15
3–4 Years 8 8 8
4 years or more 33 42 29
Options for self-management of symptoms prior to seeking medical treatment
Over the counter medications 60 60 60 0.94
Exercise/Diet/Lifestyle modifications 49 48 50 0.77
Hormonal contraceptives 34 34 34 0.99
Herbs/Supplements/Other alternative
and complementary medicines
26 37 20 0.01
Sources of information regarding fibroids
Healthcare provider 92 94 91 0.35
Health-related websites 48 49 47 0.70
Friends and family 27 36 22 0.004
Health brochure 22 32 18 0.001
Books, magazines and newspapers 19 24 17 0.09
Internet discussion forums 16 15 16 0.94
Television and radio 6 14 2 < 0.001
Needs for fibroid information
Needs general information about fibroids 38 54 29 < 0.001
Needs information about treatment options 46 59 39 0.001
Wants information about alternative treatments 46 58 39 0.004
Needs information about consequences of treatment options 44 58 37 0.001
Needs information about consequences of not having
fibroids treated
45 53 41 0.06
Found enough useful information on internet 35 21 43 < 0.001
Needs peer support 10 15 8 0.06
Sources of support
Uterine fibroid website 50 60 45 0.001
Women’s health website 48 59 43 0.003
General website 43 55 38 0.01
Women’s health group 23 35 19 < 0.001
Uterine fibroid group 21 30 18 0.001
Note: Survey weights are used to generate the above numbers.
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likely to be satisfied with the information they found on the
Internet regarding fibroids (21 vs. 43%, P < 0.001).
African-American women were more likely to seek peer
support than white women (15 vs. 8%, P = 0.06), including
support from uterine fibroid groups (60 vs. 45%, P < 0.001),
women’s health organizations (59 vs. 43%, P < 0.003), and
general websites (55 vs. 38%, P = 0.01) (Table 4). African-
American women also generally utilized women’s health (35
vs. 19%) and uterine fibroid groups (30 vs. 18%, P < 0.001 for
both) more often than white women.
Discussion
Uterine fibroids are a major source of morbidity for re-
productive-age women. While this statement is often re-
peated, the current report quantitates and articulates the
magnitude of this morbidity, especially for African-American
women.
This study documents that African-American women ap-
pear to report more severe symptoms and resulting functional
impairment due to fibroids. Given the substantial data
showing that African-American women have more objective
indications of severe disease, including earlier age of onset,
more fibroids, and bigger uteri, the increased symptoms and
impairment they report likely result from their increased
disease burden and not just racial differences in reporting.2,5,7
Moreover, the disparities are compounded at every step:
African-American women are more likely to experience
symptoms longer before seeking treatment. As African-
American women seek treatments, they have more concerns
regarding the complications and consequences of treatment
options. They then find it harder to get valid information on
treatment risks and benefits from a variety of sources.
The disparity in the way that uterine fibroids affect African-
American women regarding fertility and pregnancy is par-
ticularly striking for two reasons. First, with an earlier onset of
the disease, in their late 20s rather than their 30s on average,
fibroids are more likely to have an impact on childbearing
plans for African-American women.7 Second, the historical
issues of limiting the reproductive freedom of women of color
through practices such as compulsory sterilization resonate
with these findings and underlie the concerns African-
American women of all ages have articulated about uterine
fibroids, particularly their impact on fertility and childbear-
ing. For some UFS-QOL outcomes, age appeared to be an
effective modifier, with younger African-American women
(29–39) bearing higher risks of reporting these outcomes than
older African-American women. Thus, educating African-
American women about appropriate fertility-preserving al-
ternatives to hysterectomy is a key goal for clinicians.22,23
Multiple studies have demonstrated that cultural, ethnic,
and educational background plays a role in a woman’s se-
lection of hysterectomy.24–28 However, this is the first study to
examine the effect of race on assessment of information re-
garding all fibroid therapies. Further studies are needed to
explore patient-provider communication with African-
American women. Development of decision support tools,
informed by providers and patients, may help to facilitate
appropriate discussions about alternative treatments. It is
interesting that the highest response rate in our study came
from the Southeast where hysterectomy rates have histori-
cally been highest.29
The economic impact of fibroids is also likely under-
estimated based on this survey.30–32 A recent publication33
suggested that previously reported cost for fibroids was un-
derestimated by excluding the costs of obstetrical outcomes
related to fibroids, raising costs of this disease to $5.9–34.4
billion annually in the United States. Data on lost work pro-
ductivity attributable to uterine fibroids has been limited.31,32
With data from this survey demonstrating that more than
one- quarter of women report lost work days and over one-
fifth report concerns regarding losing their job due to the
uterine fibroids, it is likely that this key parameter is sub-
stantially underestimated.
The strengths of this study are the large number of women
surveyed, the use of a population-based survey to ensure that
the respondents reflected the general U.S. population, and the
use of the only validated measure for fibroid-specific quality
of life (UFS-QOL).21 Furthermore, women were drawn from
the general population to reduce the bias from surveying
women who have sought medical treatment. This survey
substantially extends the limited data previously available by
delineating the magnitude of symptoms and the specific effect
of race on a variety of important parameters of disease and
acquisition of information about disease and treatment op-
tions.14
Limitations of the survey include the existence of some
selection bias in the overall sample due to the fact that these
women participated in an online panel. That women would
need Internet access and had above-average educational
levels should be considered when interpreting our results.
However, the use of conventional telephone surveys in the
current era of smartphone use would also likely miss a sub-
stantial segment of the population. The fact that there are
neither educational nor employment differences between ra-
ces for women participating in this survey suggests that while
the generalizability to the entire U.S. population may be af-
fected, these specific demographic factors do not influence the
racial differences.
This survey also relied on self-report of fibroids, so some
misdiagnosis likely occurred. While validation of self-report
has not been carried out in the subjects we surveyed, previous
data suggests that self-report is accurate for over 90% of wo-
men with uterine leiomyomas.5,34 Additionally, we did not
administer the complete UFS-QOL instrument, so detailed
assessment of QOL domains is not possible. Finally, detailed
information regarding prior fibroid treatment and perceived
success of earlier treatments may be potential confounders
that we were unable to adjust for in the multivariate analyses.
Conclusions
In summary, the burden of uterine fibroids is even more
extensive for African-American women compared to white
women than previously reported. This disparity has real-
world consequences and should set the agenda for the next
generation of research on uterine fibroids.
First, these findings likely have cost implications for both
individuals and the healthcare system and the existing liter-
ature on costs of uterine fibroids is limited.30–33, 35–40 For ex-
ample, the cost of both missed work days and limitations on
productivity and career advancement need to be studied to
understand the true costs of uterine fibroids. Additionally, the
fact that African-American women report significant delays in
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diagnosis has implications for ambulatory healthcare costs
and for potentially decreased efficacy of subsequent treatment
due to advanced disease. A comprehensive assessment of the
direct and indirect healthcare costs of this disease appears to
be in order.
Understanding and addressing the needs of this population
of severely affected women with uterine fibroids are key goals
for healthcare providers and researchers. This substantial
unmet need was recently recognized when the Patient Cen-
tered Outcomes Research Institute (http://www.pcori.org/
2012/boston-board-decisions/) designated uterine fibroids a
research priority. Key priorities for this type of research will
likely include developing a severity algorithm to aid in clas-
sification of disease for research and developing user-friendly
decision aids that take into account the racial differences
demonstrated in this study so that all women, but especially
African-American women, can have access to the best evi-
dence in a fashion they can use most.
Last, but not least, studying treatments for uterine fibroids
is critical. Hysterectomy has been the primary therapeutic tool
in the gynecologic armamentarium for uterine fibroids for
decades. The fact that the cumulative incidence of hysterec-
tomy in the United States is 45%, despite the fact that only 8%
of hysterectomies are performed for cancer diagnoses and
49% are for uterine fibroid and abnormal bleeding, demon-
strates this overreliance on hysterectomy.41,42 Moreover, there
is substantial data on the regional variation of hysterectomy,
with rates higher in the southeastern United States, where the
relative concentration of African-American women is high-
est.29,43 However, the strong findings related to reproductive
concerns in African-American women of all ages suggests that
educating this particular group about alternative to hyster-
ectomy is especially important.
More research needs to be done regarding uterine-sparing
alternatives to hysterectomy. A variety of effective techniques
can be used based on the woman’s symptoms, her fibroid
burden, and her reproductive plans.4 However, there is little
comparative effectiveness research to guide therapy.13,44,45 The
number of randomized clinical trials (RCTs) comparing dif-
ferent fibroid treatments performed in the United States and
those with racially diverse participants is especially small.15
Although we have gained key information comparing uterine
artery embolization (UAE) to surgery from RCTs performed in
Europe, these studies have few women of African origin and
differences in healthcare economics in Europe make their
translation to U.S. populations difficult.46–48 There is only one
ongoing trial comparing two major interventional alternatives
to hysterectomy, UAE and magnetic resonance-guided focused
ultrasound surgery (MRgFUS).49
There is also evidence that at least some of the disparity
related to fibroids may be due to biologic differences between
black and white women, including differences in predisposi-
tion genes and environmental exposures such as vitamin D
deficiency.50,51 Given the high prevalence of this disease, un-
derstanding its biology in order to design early intervention or
prevention strategies should be the mandate for the future.
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